Novartis Pruned Pipeline Producing Attractive Respiratory And Neurology Fruits
Novartis executives highlighted their stars from its refined pipeline during the company’s first R&D day since Vas Narasimhan took the helm and after a cull that reduced the firm’s development portfolio by 20%.
You may also be interested in...
At $10.9bn, biopharma financing was at its lowest quarter of the year. GSK’s $5.1bn acquisition of oncology player Tesaro led M&As. And 13 partnerships exceeded the $1bn mark, led by two agreements focused on RNAi.
The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s, but refused to discuss ongoing studies during its fourth quarter earnings call.
Pfizer's fourth-quarter call will be the first with new CEO Albert Bourla, while Amgen will provide reassurances after US Neulasta and Epogen biosimilar launches. Also, concerns swirl around the impending impact of generics on Allergan's blockbuster Restasis, Biogen investors await news on Alzheimer's programs and M&A, and Novartis will face scrutiny of recent launches.